DiaSorin (DSRLF)
(Delayed Data from OTC)
$99.86 USD
-9.14 (-8.39%)
Updated Jun 27, 2024 12:43 PM ET
NA Value
NA Growth NA Momentum NA VGMDiaSorin S.p.A. (DSRLF) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$N/A | $N/A | $N/A | N/A% |
Price Target
DiaSorin S.p.A. does not have any price target set by analysts.
Analyst Price Targets ()
Broker Rating
DiaSorin S.p.A. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on three recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.33 | 2.33 | 2.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | Not Identified | Not Identified | Not Available | Hold |
4/8/2024 | UBS | Kavya Deshpande | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 2 |
Average Target Price | NA |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 63 of 253 |
Current Quarter EPS Est: | NA |